These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34895484)

  • 21. The cost-effectiveness of harm reduction.
    Wilson DP; Donald B; Shattock AJ; Wilson D; Fraser-Hurt N
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S5-11. PubMed ID: 25727260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modelling the impact of HIV and HCV prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania.
    Fraser H; Stone J; Wisse E; Sambu V; Mfisi P; Duran IJ; Soriano MA; Walker JG; Makere N; Luhmann N; Kafura W; Nouvellet M; Ragi A; Mundia B; Vickerman P
    J Int AIDS Soc; 2021 Oct; 24(10):e25817. PubMed ID: 34661964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimising HIV spending in 12 eastern European and central Asian countries: a modelling study.
    Ten Brink DC; Bowring AL; Martin-Hughes R; Wulan N; Xiao Y; Burke K; Tidhar T; Walsh T; Kelly SL; Shattock A; Palmer T; Maxim C; Zhang S; Scott N
    Lancet HIV; 2024 Oct; 11(10):e690-e699. PubMed ID: 39245062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis.
    Hines LA; Trickey A; Leung J; Larney S; Peacock A; Degenhardt L; Colledge S; Hickman M; Grebely J; Cunningham EB; Stone J; Dumchev K; Griffiths P; Vickerman P; Mattick RP; Lynskey M
    Lancet Glob Health; 2020 Jan; 8(1):e76-e91. PubMed ID: 31839143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study.
    Bórquez A; Guanira JV; Revill P; Caballero P; Silva-Santisteban A; Kelly S; Salazar X; Bracamonte P; Minaya P; Hallett TB; Cáceres CF
    Lancet Public Health; 2019 Mar; 4(3):e127-e136. PubMed ID: 30683587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis.
    Stone J; Degenhardt L; Grebely J; Larney S; Altice FL; Smyrnov P; Rahimi-Movaghar A; Alavi M; Young AM; Havens JR; Miller WC; Hickman M; Vickerman P
    Lancet Psychiatry; 2021 Apr; 8(4):301-309. PubMed ID: 33640039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of opioid substitution therapy on the HIV prevention benefit of antiretroviral therapy for people who inject drugs.
    Mukandavire C; Low A; Mburu G; Trickey A; May MT; Davies CF; French CE; Looker KJ; Rhodes T; Platt L; Guise A; Hickman M; Vickerman P
    AIDS; 2017 May; 31(8):1181-1190. PubMed ID: 28323752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of a police education program on HIV and overdose among people who inject drugs in Tijuana, Mexico.
    Cepeda JA; Beletsky L; Abramovitz D; Saldana CR; Kahn JG; Bañuelos A; Rangel G; Arredondo J; Vickerman P; Bórquez A; Strathdee SA; Martin NK
    Lancet Reg Health Am; 2024 Feb; 30():100679. PubMed ID: 38327278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling study.
    Nosyk B; Zang X; Min JE; Krebs E; Lima VD; Milloy MJ; Shoveller J; Barrios R; Harrigan PR; Kerr T; Wood E; Montaner JSG
    Lancet HIV; 2017 Jul; 4(7):e303-e310. PubMed ID: 28366707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
    Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
    Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upscaling prevention, testing and treatment to control hepatitis C as a public health threat in Dar es Salaam, Tanzania: A cost-effectiveness model.
    Scott N; Mohamed Z; Rwegasha J; Mbwambo J; Lemoine M; Hellard M
    Int J Drug Policy; 2021 Feb; 88():102634. PubMed ID: 31882272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug scene, drug use and drug-related health consequences and responses in Kulob and Khorog, Tajikistan.
    Latypov A; Otiashvili D; Zule W
    Int J Drug Policy; 2014 Nov; 25(6):1204-14. PubMed ID: 25449057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
    Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
    Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addressing injecting drug use in Asia and Eastern Europe.
    Wu Z; Shi CX; Detels R
    Curr HIV/AIDS Rep; 2013 Jun; 10(2):187-93. PubMed ID: 23446827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States.
    Bernard CL; Brandeau ML; Humphreys K; Bendavid E; Holodniy M; Weyant C; Owens DK; Goldhaber-Fiebert JD
    Ann Intern Med; 2016 Jul; 165(1):10-19. PubMed ID: 27110953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing HIV/AIDS resources in Armenia: increasing ART investment and examining HIV programmes for seasonal migrant labourers.
    Kelly SL; Shattock AJ; Kerr CC; Stuart RM; Papoyan A; Grigoryan T; Hovhannisyan R; Grigoryan S; Benedikt C; Wilson DP
    J Int AIDS Soc; 2016; 19(1):20772. PubMed ID: 27281790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples.
    Walensky RP; Ross EL; Kumarasamy N; Wood R; Noubary F; Paltiel AD; Nakamura YM; Godbole SV; Panchia R; Sanne I; Weinstein MC; Losina E; Mayer KH; Chen YQ; Wang L; McCauley M; Gamble T; Seage GR; Cohen MS; Freedberg KA
    N Engl J Med; 2013 Oct; 369(18):1715-25. PubMed ID: 24171517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Male circumcision at different ages in Rwanda: a cost-effectiveness study.
    Binagwaho A; Pegurri E; Muita J; Bertozzi S
    PLoS Med; 2010 Jan; 7(1):e1000211. PubMed ID: 20098721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries.
    Degenhardt L; Mathers BM; Wirtz AL; Wolfe D; Kamarulzaman A; Carrieri MP; Strathdee SA; Malinowska-Sempruch K; Kazatchkine M; Beyrer C
    Int J Drug Policy; 2014 Jan; 25(1):53-60. PubMed ID: 24113623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating the cost-effectiveness of needle-syringe programs in Australia.
    Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
    AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.